

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/606,150	06/24/2003	Robin Callan	100070.401C1	3537
500 SEED INT	7590 07/03/200 ELLECTUAL PROPERTY	EXAMINER		
701 FIFTH AVE			KIM, JENNIFER M	
SUITE 540 SEATTLE.	WA 98104		ART UNIT	PAPER NUMBER
,			1617	
			MAIL DATE	DELIVERY MODE
			07/03/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant/s)			
Office Action Summary		дриканоп но.	Applicant(s)			
		10/606,150	CALLAN ET AL.			
		Examiner	Art Unit			
		Jennifer Kim	1617			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with	the correspondence address			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DAISING OF THE MAILING OF THE M	ATE OF THIS COMMUNICA 36(a). In no event, however, may a rep rill apply and will expire SIX (6) MONTH cause the application to become ABAI	ATION. ly be timely filed HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).			
Status						
1)⊠	Responsive to communication(s) filed on <u>02 April 2007</u> .					
2a) <u></u> ☐	This action is FINAL . 2b)⊠ This action is non-final.					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims		;			
4)🛛	Claim(s) 1,3,5,6 and 8-74 is/are pending in the	application.				
	4a) Of the above claim(s) <u>16-56</u> is/are withdrawn from consideration.					
5)	5) Claim(s) is/are allowed.					
6)⊠	Claim(s) <u>1,3,5,6,8-15 and 57-74</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8)□	Claim(s) are subject to restriction and/or	election requirement.				
Applicat	ion Papers					
9)[The specification is objected to by the Examine	r.	·			
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)	The oath or declaration is objected to by the Ex	aminer. Note the attached (Office Action or form PTO-152.			
Priority (under 35 U.S.C. § 119		·			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachmen	nt/c)					
_	n(s) ce of References Cited (PTO-892)	4) T Interview Su	mmary (PTO-413)			
2) Notice	ce of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/	Mail Date			
	mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date <u>2/2/06;2/1/05</u> .	5)	ormal Patent Application			

Application/Control Number: 10/606,150

Art Unit: 1617

DETAILED ACTION

Applicant's election of species with traverse of trisodium citrate (for the citrate), sodium acetate (for the acetate) and sodium lactate (for the lactate) is acknowledged. However, in view of Applicant's persuasive argument, the requirement of the species election made on the last Office Action is withdrawn. Accordingly, claims 1, 3, 5, 6, 8-15 and 57-74 are being examined on the merits and claims 16-56 are withdrawn from consideration.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Application/Control Number: 10/606,150

Art Unit: 1617

Claims 1, 3, 5, 6, 8-15 and 57-74 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 6,610,206B1 in view of Gupta (U.S.Patent No. 6,779,468 B1).

The difference between the claims in the patent and instant Application is incorporation of iron complex or iron salts set forth in claims 57-60. However, to incorporate noncolloidal ferric compound such as ferric pyrophosphate to dialysis composition in order to prevent or treat iron deficiency is obvious in view of Gupta. (abstract, column 1, lines 10-17, column 4, lines 15-23). Therefore, it would have been obvious to one of ordinary skill in the art, at the time the invention was made to incorporate ferric compounds such as ferric pyrophosphate well known by Gupta routinely incorporated in dialysis composition in order to supplement iron to dialysis patients.

None of the claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jennifer Kim Patent Examiner Art Unit 1617 Page 4

Jmk June 11, 2007